Profile

Liisa Bayko

Chief Financial Officer and Treasurer, Kalaris Therapeutics, Inc.

In the seat. First published here October 28, 2026; built from records as of October 28, 2026.

Liisa Bayko has been Chief Financial Officer and Treasurer of Kalaris Therapeutics, Inc. since July 20, 2026, according to the company's filing of July 20, 2026.¹

The filing gives Liisa Bayko's previous role as Managing Director, Biotech Equity Research at Evercore ISI.¹ Liisa Bayko joined from outside Kalaris Therapeutics, Inc., by the record's reading of the filing.¹

Seats

The seat in the record

Company	Title as filed	Standing	Filings
Kalaris Therapeutics, Inc. (KLRS) Biological Products, (No Diagnostic Substances)	Chief Financial Officer and Treasurer	In the seat	1

Company names link to the company's page in the record at CFO Tribune, which holds the seat history.

The record

Filing by filing, latest first

July 20, 2026effective
Kalaris Therapeutics, Inc. appointed Liisa Bayko as Chief Financial Officer and Treasurer, effective July 20, 2026.
On July 16, 2026, the Board of Directors (the “Board”) of Kalaris Therapeutics, Inc. (the “Company”) appointed Liisa Bayko as Chief Financial Officer and Treasurer of the Company, effective as of July 20, 2026 (the “Effective Date”).
[1] Filing by Kalaris Therapeutics, Inc., filed with the SEC on July 20, 2026. Read the filing. The record at CFO Tribune.

Sources

Current report filed with the SEC, Kalaris Therapeutics, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed July 20, 2026. sec.gov; record.

Corrections and removal

If a line here is wrong, or Liisa Bayko wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.